The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated and Medicare-reimbursed, blood‑based monitoring solution for viral‑mediated cancers. The definitive agreement provides for an up-front cash consideration of $160 million with up to an additional $100 million based on the achievement of revenue milestones.
Read the full article: CareDx Announces Agreement to Acquire Naveris, a Leader in Viral-Mediated Cancer MRD Surveillance Testing //
Source: https://www.businesswire.com/news/home/20260428112222/en/CareDx-Announces-Agreement-to-Acquire-Naveris-A-Leader-in-Viral-Mediated-Cancer-MRD-Surveillance-Testing